MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)

The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment. This treatment is called metastasis-directed radiotherapy (MDRT). The usual treatment for prostate cancer that has spread to other parts of the body is to give lifelong treatment with hormone therapy (also known as androgen deprivation therapy or ADT). Participants may also be given prostate RT even if the disease is metastatic. Participants will receive hormone therapy (the standard t

Trial Details

NCT ID
NCT06150417
Phase
PHASE2
Sponsor
Case Comprehensive Cancer Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Androgen deprivation therapy (ADT)
  • Androgen receptor signaling inhibitor (ARSI)
  • Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
  • Metastasis directed radiotherapy (MDRT)
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • Participant must be ≥ 18 years of age.
  • Participant must have an ECOG performance status ≤ 1.
  • Histologic confirmation of prostate adenocarcinoma of the prostate gland, with evidence of metastasis on imaging by conventional imaging (MRI, CT, …
  • There must be at least 10-15 unstained slides from 2 cores of the highest tumor cellularity available.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →